Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

FSD Pharma closes $16 million-plus sale of non-core assets

Stockhouse Editorial
1 Comment| May 11, 2022

{{labelSign}}  Favorites
{{errorMessage}}

Click to enlargeCoburg ON-based FSD Pharma Inc. (CSE: HUGE) – a life sciences holding company dedicated to building a portfolio of assets and biotech solutions – has announced the closing of the sale of the Company’s former cannabis processing facility located in Cobourg, Ontario, Canada for gross proceeds of CDN$16,400,000 in cash.

Highlights of Sale:

  • Nets CDN$15,480,780 cash in non-dilutive capital
  • Current cash position of approximately CAD$50 million or approximately CDN $1.30 per share with only 38.4 million shares issued
  • Profit realized on the sale of the non-core asset which was acquired by FSD Pharma in 2017 for CDN$5.5 million
  • FSD continues to enhance shareholder value via the sale of the non-core asset, as well as via the share repurchase plan, which has so far in 2022 has reduced the number of shares issued/outstanding by 1.52 million shares.


Click here for full news release.


About FSD Pharma

FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. – a wholly owned subsidiary – is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (PEA) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (Lucid) – a wholly owned subsidiary – is focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.

New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.

For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today